切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2018, Vol. 12 ›› Issue (06) : 500 -502. doi: 10.3877/cma.j.issn.1674-3946.2018.06.016

所属专题: 文献

论著

COX-2、CD31及CD105与胃癌分期及预后的关联性分析
刘晔1,(), 李葵芳1, 顾慧1   
  1. 1. 214400 江苏江阴,南京中医药大学江阴附属医院病理科
  • 收稿日期:2018-05-22 出版日期:2018-12-26
  • 通信作者: 刘晔

Correlation analysis of the COX-2, CD31 and CD105 expression and the staging or prognosis of gastric cancer

Ye Liu1,(), Kuifang Li1, Hui Gu1   

  1. 1. Department of Pathology, Jiangyin Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu, 214400, China
  • Received:2018-05-22 Published:2018-12-26
  • Corresponding author: Ye Liu
  • About author:
    Corresponding author: Liu Ye, Email:
  • Supported by:
    Project of Jiangsu Provincial Science and Technology Department(NO.20160 B122)
引用本文:

刘晔, 李葵芳, 顾慧. COX-2、CD31及CD105与胃癌分期及预后的关联性分析[J/OL]. 中华普外科手术学杂志(电子版), 2018, 12(06): 500-502.

Ye Liu, Kuifang Li, Hui Gu. Correlation analysis of the COX-2, CD31 and CD105 expression and the staging or prognosis of gastric cancer[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2018, 12(06): 500-502.

目的

探讨环氧合酶-2(COX-2)、血管标志物CD31及CD105与胃癌分期及预后的关联性分析。

方法

采用免疫组织化学方法检测2016年1月至2018年4月期间胃癌根治术48例患者病理标本中COX-2、CD31及CD105的表达水平,使用SPSS 19.0统计软件进行统计分析。CD31、CD105、COX-2表达阳性率采用χ2检验进行比较,相互关系检验采用Spearman相关分析。P<0.05差异有统计学意义。

结果

COX-2 、CD31及CD105蛋白表达与胃癌分期及预后显著相关(P<0.05),而与患者的年龄、性别、肿瘤大小、肿瘤部位因素无关(P>0.05)。COX-2在胃癌组织中的阳性表达率为76.5%,而CD31及CD105在胃癌组织中的阳性表达率分别为68.8%和70.8%,COX-2与CD31(r=0.532, P=0.032)及CD105(r=0.544, P=0.029)的表达均存在相关性。

结论

COX-2、CD31及CD105蛋白在胃癌组织中高表达,且COX-2的表达与血管标志物CD31及CD105的表达存在相关性,可协同作为判断胃癌分期及预后的临床指标。

Objective

To investigate the correlation of the COX-2, CD31 and CD105 expression and the staging or prognosis of gastric cancer.

Methods

Immunohistochemistry was used to detect the expression levels of COX-2, CD31 and CD105 in 48 patients underwent radical gastrectomy from January 2016 to April 2018. Statistical analysis was performed by using SPSS 19.0 statistical software. The positive rates of CD31, CD105 and COX-2 expression were examined by using χ2 test, and the correlation test was performed by using Spearman correlation analysis. A P value < 0.05 was considered as statistically significant difference.

Results

The expression of COX-2, CD31 and CD105 was significantly correlated with the staging and prognosis of gastric cancer (P<0.05), but not with age, sex, tumor size and tumor location of these patients (P>0.05). The positive expression rate of COX-2 in gastric cancers was 76.5%, while the positive expression rates of CD31 and CD105 in gastric cancers were 68.8% and 70.8%, respectively. There was a correlation between COX-2 expression and vascular marker proteins CD31 (r=0.532, P=0.032) and CD105 (r=0.544, P=0.029).

Conclusion

COX-2, CD31 and CD105 are highly expressed in gastric cancer tissues. The expression of COX-2 is correlated with the expression of CD31 and CD105 in vascular markers which could be used as a clinical indicator for judging the staging and prognosis of gastric cancer.

表1 COX-2、CD31、CD105表达与48例胃癌患者临床病理资料的特征(例)
图1 COX-2在胃癌组织中的阳性表达( DAB,×200)
图2 CD31和CD105在胃癌组织中的阳性表达( DAB,×20)
表2 COX-2与血管标志物蛋白CD31及CD105表达相关性分析
[1]
Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J].International journal of cancer, 2015, 136(5):E359-E386.
[2]
Liu XJ, Li SL, Li JS, et al.Long non-coding RNA ZEB1-AS1 is associated with poor prognosis in gastric cancer and promotes cancer cell metastasis[J].European review for medical and pharmacological sciences, 2018, 22(9):2624-2630.
[3]
Bai XY, Liu YG, Song W, et al.Anticancer activity of tetrandrine by inducing pro-death apoptosis and autophagy in human gastric cancer cells[J].The Journal of pharmacy and pharmacology, 2018, 70(8):1048-1058.
[4]
张旺清,李宝玉,刘娟,等. EpCAM和CD44在胃癌中的表达及临床意义[J]. 中国临床研究,2014, 27(12):1441-1444.
[5]
胡承浩,罗清钦,张丹峰,等. Toll样受体4在胃癌中的表达及其临床意义[J]. 中国临床研究,2018, 31(4):27-30.
[6]
Zhang YH, Ma K, Liu JR, et al.γ-tocotrienol inhibits the invasion and migration of human gastric cancer cells through downregulation of cyclooxygenase-2 expression[J].Oncology Reports, 2018, 40(2):999-1007.
[7]
Ren J, Liu J, Sui X.Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis[J].Journal BUON, 2018, 23(3):665-671.
[8]
Zhao J, Wen S, Wang X, et al. modulates cyclooxygenase-2 and 15-hydroxy prostaglandin dehydrogenase in gastric cancer[J].Oncology Letters, 2017, 14(5):5519-5525.
[9]
Basilio-de-Oliveira RP, Pannain VL.Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors[J].World Journal of Gastroenterology, 2015, 21(22):6924-6930.
[10]
Micu GV, Stǎniceanu F, Sticlaru LC, et al.Correlations Between the Density of Tryptase Positive Mast Cells (DMCT) and that of New Blood Vessels (CD105+) in Patients with Gastric Cancer[J].Rom J Intern Med, 2016, 54(2):113-120.
[11]
左婷婷,郑荣寿,曾红梅,等.中国胃癌流行病学现状[J].中国肿瘤临床,2017,44(1):52-58.
[12]
Venerito M, Vasapolli R, Rokkas T, et al.Gastric cancer: epidemiology, prevention, and therapy[J].Helicobacter, 2018, 23 Suppl 1:e12518-e12518.
[13]
Setoyama T, Miyamoto SI, Nikaido M, et al.Evaluation of the safety and efficacy of endoscopic treatment for early gastric cancers in patients aged over 80 years[J].Nihon Shokakibyo Gakkai zasshi, 2018, 115(5):467-475.
[14]
Rosário Pinheiro DD, Harada ML, Rodriguez Burbano RM, et al.COX-2 gene expression and methylation profile in Sapajus apella as an experimental model for gastric adenocarcinoma[J].Genet Mol Biol, 2018, 41(2):496-501.
[15]
Li B, Nie Z, Zhang D, et al.Roles of circulating endothelial progenitor cells and endothelial cells in gastric carcinoma[J].Oncol Lett, 2018, 15(1):324-330.
[16]
Gurzu S, Orlowska J, Sugimura H, et al.Immunohistochemical features and staging of early gastric cancer[J].Arch Med Sci, 2017, 13(6):1373-1382.
[1] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[2] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[7] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[8] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[9] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[10] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[11] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 刘海旺, 施海, 尚利峰. 不同吻合器在腹腔镜远端胃癌根治术Roux-en-Y式吻合中的应用对比[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 643-646.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要